Michel Lagarde

Michel Lagarde brings extensive global experience helping pharmaceutical and biotech companies succeed by delivering critical products and services. He currently serves as Executive Vice President and Chief Operating Officer at Thermo Fisher Scientific Inc., a supplier of analytical instruments, life sciences solutions, specialty diagnostics, and laboratory, pharmaceutical and biotechnology services. In this role, he is responsible for Thermo Fisher's Pharma Services, Customer Channels, BioProduction, Analytical Instruments, Laboratory Products and Clinical Research businesses as well as its Corporate Accounts function and Chief Medical Office.

Before Thermo Fisher, Mr. Lagarde was President and Chief Operating Officer at Patheon N.V., a pharma services company, from 2016 to 2017, and Managing Director at JLL Partners, a private equity firm focused on health care services, from 2008 to 2016. Earlier in his career, he spent 12 years at Philips, a global leader in health technology, in a range of finance roles across several international markets. He served as Finance Controller of Philips Electronics Hong Kong, where he was responsible for a $1 billion industrial footprint.

Career History

• President and Chief Executive Officer, West Pharmaceutical Services, Inc. (effective August 31, 2026)
• Executive Vice President and Chief Operating Officer, Thermo Fisher Scientific Inc. (2017–2026)
• President and Chief Operating Officer, Patheon N.V. (2016–2017)
• Managing Director, JLL Partners (2008–2016)
• Various Finance Roles, Philips (12 years)

He holds a Bachelor of Business Administration (BBA) from European University in Antwerp, Belgium, and an executive master's degree in finance and control from Maastricht University in the Netherlands. In 2023, Mr. Lagarde joined the Board of Directors of Vertex Pharmaceuticals, where he serves as Chair of the Audit and Finance Committee.

What Michel Lagarde could bring to President and CEO of West Pharmaceutical Services: Lagarde brings deep operational expertise from leading critical pharmaceutical services divisions at one of the life sciences industry's largest companies. His track record managing complex global operations, combined with his finance acumen refined over decades and board-level governance experience, positions him to drive innovation and operational excellence at West while navigating the evolving injectable drug delivery market and addressing challenges such as manufacturing scale and service reliability.